FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF ...Middle East

Medscape - News
The newly approved labeling for sacubitril/valsartan (Entresto) is simply for "chronic heart failure" but almost teasingly adds, "the benefits are most clearly evident" at below-normal LVEF. FDA Approvals

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF )

Apple Storegoogle play

Also on site :



Latest News